04:42 PM EDT, 06/18/2025 (MT Newswires) -- (Updates with denial of a news report in the sixth paragraph.)

Aurora Cannabis ( ACB ) on Wednesday said its fourth-quarter net loss narrowed slightly while revenue rose.

For the quarter, the net loss shrunk to $17.2 million from $20.3 million in the prior year period.

Net revenue climbed by a third to $90.5 million, beating a consensus estimate of $88.8 million, according to FactSet. The increase was due to 48% growth in Aurora's global medical cannabis business and 32% jump in plant propagation sales. Aurora's consumer cannabis sales declined 20% to $10.2 million as the company prioritized higher-margin medical cannabis.

For its fiscal first quarter, Aurora is guiding to continued strong global cannabis revenue and seasonally higher revenue for plant propagation.

"Specific to Q4 2025, we ended our banner fiscal year by further strengthening our business model. International revenue more than doubled, representing 61% of global medical cannabis net revenue," said Chief Executive Miguel Martin. "Plant propagation also increased significantly as we benefited from peak seasonality along with organic expansion."

After market closes, Aurora also denied a report it agreed to acquire a New Zealand medical cannabis company. It said an unnamed news site was "incorrectly stating that Aurora has agreed to acquire New Zealand based MedLeaf Therapeutics. The Company has not entered into any such agreement, has had no discussions with MedLeaf Therapeutics with respect to any business combination transaction, and has not made any statement or filed any information pertaining to any such transaction".

The company's shares closed down $1.62 to $6.40 on the Toronto Stock Exchange.